September 14, 2020

 | Pan Tumor (3) | Liquid Biopsy and ctDNA (12) | Endometrial (1)

 

For full coverage, contact us at veri@larvol.com

 

PAN TUMOR

 
MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan-cancer. (PubMed, Clin Transl Med) – Sep 9, 2020 – No abstract available
 
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. (PubMed, JCO Precis Oncol) – Sep 10, 2020 – “Biallelic BRCA1/2 alterations were associated with elevated gLOH in diverse cancer types, including those not traditionally associated with BRCA1/2 cancer syndromes. Biomarker development for PARP inhibitors should integrate methods to distinguish biallelic from monoallelic BRCA1/2 status, and biallelic BRCA1/2 alteration should be broadly evaluated across cancer types as a biomarker for underlying HRD and PARP inhibitor sensitivity.”
 
Pan-cancer analysis reveals that ACE2 is positively associated with immunotherapy response and is a potential protective factor for cancer progression. (PubMed, Comput Struct Biotechnol J) – Sep 10, 2020 – “These results suggest that ACE2 is a potential protective factor for cancer progression. Our data may provide potential clinical implications for treating cancer patients infected with SARS-CoV-2.”
 
Top↑


 

LIQUID BIOPSY AND ctDNA

 
MRD versus stringent complete response to predict outcomes in multiple myeloma (DocNewswire) – Sep 11, 2020 – “Our results confirm that response assessment according to the sCR criteria does not predict a different outcome for [patients with] MM with CR. However, more sensitive techniques, including both MFC and NGS of immunoglobulin genes, might identify patients with different prognoses, even among patients with sCR.”
 
Helio Health collaboration aims to evaluate liquid biopsy test for liver cancer (GenomeWeb) – Sep 10, 2020 – “Irvine, California-based Helio Health on Thursday announced a multicenter collaboration to compare the performance of its circulating tumor DNA assay with abbreviated magnetic resonance imaging and ultrasound for hepatocellular carcinoma (HCC) screening.”
 
A biocomposite-based rapid sampling assay for circulating cell-free DNA in liquid biopsy samples from human cancers (Nature) – Sep 10, 2020 – “The biocomposite platform allowed the isolation of high purity and quantity cfDNAs from the plasma of 13 cancer patients (three colorectal cancer and ten pancreatic cancer samples) without requiring a lysis step or special equipment. The biocomposite platform may be useful to isolate cfNAs for the diagnosis and treatment of cancers in clinical applications.”
 
Comparative analysis of genomic alterations across castration-sensitive and castration-resistant prostate cancer via circulating tumor DNA sequencing (Physicians Weekly) – Sep 10, 2020 – “Through genomic profiling of prostate cancer across clinical states, we identified a similar frequency of deleterious germline alterations between patients with CSPC and mCRPC. We explored the genomic diversity of AR and DDR pathway genes between patients with mCSPC and mCRPC. Higher alteration frequencies of and were observed in our mCRPC cohort than in the SU2C-PCF cohort. Our findings support the view that ctDNA sequencing could guide clinical treatment for metastatic prostate cancer.”
 
Grail files for $100M IPO ahead of 2021 launch of multi-cancer liquid biopsy (DocNewswire) – Sep 09, 2020 – “Grail on Wednesday filed with the U.S. Securities and Exchange Commission to raise up to $100 million in an initial public offering ahead of the anticipated launch of its multi-cancer liquid biopsy screening test for use in asymptomatic individuals.”
 
North American research collaboration to evaluate liquid biopsy for more accurate and rapid assessment of lung cancer patient response to immunotherapy (CTG) – Sep 09, 2020 – “The Cancer Research Institute (CRI) and The Mark Foundation for Cancer Research have launched an innovative clinical trial that aims to demonstrate the utility of a novel, ultra-sensitive biomarker-directed blood test, or liquid biopsy, in assessing cancer patient responses to immunotherapy.”
 
Refined stratification based on baseline concomitant mutations and longitudinal circulating tumor DNA monitoring in advanced EGFR-mutant lung adenocarcinoma under gefitinib treatment (Science Direct) – Sep 08, 2020 – “The patients with baseline co-mutations and ctDNA non-clearance at first visit might require combined therapy due to limited survival benefit of EGFR-TKI monotherapy. We proposed a refined stratification mode for the whole-course management of EGFR-mutant LUAD.”
 
HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery (Research Square) – Sep 08, 2020 – “We suggested that HER2 testing in liquid biopsy could be used as an auxiliary method to analysis of HER2 status in tumor tissue in gastric or esophagogastric junction cancers.”
 
Biocept executes in-network provider agreement with Health Net Federal Services extending coverage for its liquid biopsy oncology platform to the TRICARE West region network (Biospace) – Sep 08, 2020 – “Biocept, Inc…announces it has entered into an agreement with Health Net Federal Services LLC to be an in-network provider for its Target Selector™ liquid biopsy oncology platform for the TRICARE West (TriWest) region network. TriWest provides healthcare services to approximately three million members of the U.S. military and their families.”
 
Direct enhanced detection of multiple circulating tumor DNA variants in unprocessed plasma by magnetic-assisted bioelectrocatalytic cycling (ACS Publications) – Sep 08, 2020 – “The described ctDNA SNV assay enables detection of clinically relevant ctDNA SNVs in melanoma (BRAFV600E, KITL576P and NRASQ61K) from unprocessed plasma samples with unprecedented 0.005% detection sensitivity, ultrabroad dynamic range over four orders of magnitude, and excellent single base specificity.”
 
Association of GATA3 polymorphisms with minimal residual disease and relapse risk in childhood acute lymphoblastic leukemia (JNCI) – Sep 07, 2020 – “Inherited GATA3 variant rs3824662 strongly influences ALL response to remission induction therapy and is associated with relapse. This work highlights the potential utility of germline variants in upfront risk stratification in ALL.”
 
Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer (Nature) – Sep 07, 2020 – “ctDNA detection at the end of neoadjuvant chemotherapy indicated significantly worse relapse-free survival (HR = 0.29 (95% CI 0.08–0.98), p = 0.046), and overall survival (HR = 0.27 95% CI 0.075–0.96), p = 0.043). Hence, individualized multi-variant ctDNA testing during and after NAC prior to surgery has prognostic and predictive value in early TNBC patients.”
 

Top↑


 

 

CERVICAL

 

OC-001 / Ocellaris Pharma
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (clinicaltrials.gov) – Aug 21, 2020 – P1b/2a; N=80; Recruiting; Sponsor: Ocellaris Pharma, Inc.; Not yet recruiting –> Recruiting
 
Yervoy (ipilimumab) / Ono Pharma, BMS
Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929). (PubMed, Clin Cancer Res) – Aug 22, 2020 – “Our data indicate that CRT alone and combined with ipilimumab immunotherapy show immune modulating activity in women with locally advanced cervical cancer and may be a promising therapeutic option for the enhancement of anti-tumor immune cell function after primary CRT for this population at high-risk for recurrence and metastasis. Several key immune biomarkers were identified that were associated with clinical response.”
 
geptanolimab (GB226) / Apollomics
A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive (clinicaltrials.gov) – Aug 21, 2020 – P2; N=80; Recruiting; Sponsor: Genor Biopharma Co., Ltd.; Trial completion date: Jul 2020 –> Jul 2021; Trial primary completion date: Jun 2020 –> Dec 2020

 

Top↑


 

ENDOMETRIAL

 
Herceptin (trastuzumab) / Roche; trastuzumab biosimilar / Hetero
Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity. (PubMed, Int J Gynecol Pathol) – Sep 9, 2020 – “Frequent heterogeneity of HER2 protein expression combined with the possibility of a spatially more heterogenous sampling of endometrial cavity in biopsies and curettings, and the potential differences in specimen handling/fixation between the 2 specimen types may explain our findings. HER2 testing of multiple specimens may help identify a greater proportion of patients eligible for targeted trastuzumab therapy and should be taken into account in future efforts of developing endometrial cancer-specific HER2 testing algorithm.”

 

Top↑